THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [6.1] ID: TIP-MED-000091 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Levothyroxine Sodium (Thyroxine — L-T4)

Active Ingredient / Scientific Identity: Levothyroxine Sodium • Class: Synthetic Thyroid Hormone (L-Thyroxine; Converted Peripherally to Active Triiodothyronine T3)

⚖️ Compare Profile

1. Clinical & Scientific Overview

Levothyroxine Sodium (Thyroxine — L-T4) (TIP-MED-000091, Reference Code [6.1]) is classified under Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06) as a Synthetic Thyroid Hormone (L-Thyroxine; Converted Peripherally to Active Triiodothyronine T3). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 06 [6.1], p. 72): Thyronorm (Abbott), Eltroxin (GSK), Lethyrox (Intas), Thyrox (Macleods), Thyroup (Lupin) — Strengths & Forms: Oral Uncoated Tablets (Fine Microgram Gradations): 12.5 mcg, 25 mcg, 37.5 mcg, 50 mcg, 62.5 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg
Representative Indian Market Examples (Edition 2.7 Ch 06 [6.1], p. 72): Thyronorm (Abbott), Eltroxin (GSK), Lethyrox (Intas), Thyrox (Macleods), Thyroup (Lupin) — Strengths & Forms: Oral Uncoated Tablets (Fine Microgram Gradations): 12.5 mcg, 25 mcg, 37.5 mcg, 50 mcg, 62.5 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg
Dosage Forms & Available Strengths:
Oral Uncoated Tablets (Fine Microgram Gradations): 12.5 mcg, 25 mcg, 37.5 mcg, 50 mcg, 62.5 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Synthetic L-thyroxine (T4) acts as an endogenous prohormone reservoir that undergoes peripheral outer-ring 5'-deiodination (by Type 1 and Type 2 iodothyronine deiodinases in liver, kidney, and target tissues) to form metabolically active Triiodothyronine (T3). T3 enters the cell nucleus and binds Thyroid Hormone Receptors (TR-α1, TR-β1/β2) bound to Thyroid Response Elements (TREs), regulating basal metabolic rate, thermogenesis, lipid clearance, and neurodevelopment.

4. Therapeutic Indications & Evidence-Supported Uses

  • Primary, secondary (pituitary), and tertiary (hypothalamic) hypothyroidism
  • Congenital hypothyroidism (cretinism) in neonates and infants
  • Pituitary TSH suppression in differentiated thyroid carcinoma
  • Myxoedema coma (intravenous or crushed loading protocol)

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adults: Full replacement ~1.6 mcg/kg/day orally once daily (typically 50–125 mcg/day). In elderly (>60 yr) or ischaemic heart disease: start low at 12.5–25 mcg/day and titrate every 6 weeks based on serum TSH.

Administration & Meal Timing: Oral; take on an empty stomach with a full glass of water strictly 30–60 minutes before breakfast.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
No dose adjustment required; oral absorption must be monitored in severe malabsorption.
Elimination & Renal Adjustment:
No dose adjustment required; check free T4 and TSH.
Hepatic Impairment Considerations:
No dose adjustment required; oral absorption must be monitored in severe malabsorption.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Untreated acute adrenal insufficiency (can precipitate fatal acute Addisonian adrenal crisis)
  • Acute myocardial infarction or untreated thyrotoxicosis

Key Clinical Precautions: No dose adjustment required; oral absorption must be monitored in severe malabsorption.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Iatrogenic subclinical/overt hyperthyroidism (palpitations, sinus tachycardia, atrial fibrillation, tremor, insomnia, heat intolerance)
  • Accelerated bone mineral density loss / osteoporosis if TSH is chronically over-suppressed (<0.1 mIU/L)
  • Precipitation of angina pectoris or heart failure in elderly patients with occult coronary artery disease
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Calcium carbonate, Ferrous sulphate, Antacids (Al/Mg), Sucralfate, Sevelamer, PPIs: chelate T4 in the gut and reduce absorption — separate by at least 4 hours
  • Enzyme inducers (Phenytoin, Carbamazepine, Rifampicin): accelerate hepatic T4 clearance and increase dose requirement
  • Warfarin: Levothyroxine increases catabolism of vitamin K-dependent clotting factors, potentiating Warfarin INR
  • Pregnancy / Oestrogens: increase hepatic TBG synthesis, requiring a 25%–50% increase in Levothyroxine dose during pregnancy

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Take first thing every morning on an empty stomach with plain water, 30–60 minutes before tea, coffee, or breakfast.
  • Wait at least 4 hours before taking calcium tablets, iron supplements, or antacids.
  • During pregnancy, thyroid hormone requirements increase by 30%–50% — never stop Levothyroxine during pregnancy.

Storage, Stability & Dispensing Safeguards: Store below 25°C in tightly closed amber glass bottles protected from light and moisture.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.